The data is early-stage and the path to clinical development is undefined. Traders should watch for partnership announcements or clinical trial initiation as the next catalysts, but the high historical failure rate of similar GLMD catalysts suggests caution.
Price Chart
Executive Summary
Galmed Pharmaceuticals announced pre-clinical results showing that Aramchol combined with enzalutamide (Xtandi) produced a 3-4 fold increase in cell death in a prostate cancer cell line compared to enzalutamide alone. The company plans to initiate partnership discussions based on a recently submitted patent application for the combination.
Key Facts
- Aramchol + enzalutamide combination showed 3-4 fold increase in cell death vs enzalutamide alone in VCaP prostate cancer cell line.
- Global sales of Xtandi (marketed by Astellas and Pfizer) were approximately $8 billion in 2024 and $6 billion in 2025.
- Main composition of matter patents for enzalutamide expire in 2026 in Europe and 2027 in the US, with a US price cut scheduled to begin in 2027.
- Galmed has submitted a patent application for the combination and plans to initiate discussions with potential partners.
- This is pre-clinical data only; no clinical trials have been initiated for this combination in prostate cancer.
Financial Impact
Pre-clinical data with no disclosed financial terms; potential partnership value is speculative at this stage.
Risk Factors
- Pre-clinical data may not translate to clinical efficacy in humans.
- No timeline for clinical development or regulatory pathway for the combination.
- Company has limited financial resources ($4M market cap) to fund clinical development without partnership or financing.
- Competing SCD1 inhibitors and combination therapies for prostate cancer are in development by larger players.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-038663 |
| Document: form6-k.htm | 0001493152-26-038663 |
| Document: 0001493152-26-038663-index-headers.html | 0001493152-26-038663 |
| Document: 0001493152-26-038663-index.html | 0001493152-26-038663 |
| Document: 0001493152-26-038663.txt | 0001493152-26-038663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers